Takeda Pharmaceutical Co Ltd ADR (TAK) - Total Liabilities
Based on the latest financial reports, Takeda Pharmaceutical Co Ltd ADR (TAK) has total liabilities worth $7.77 Trillion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Takeda Pharmaceutical Co Ltd ADR - Total Liabilities Trend (2001–2025)
This chart illustrates how Takeda Pharmaceutical Co Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Takeda Pharmaceutical Co Ltd ADR to evaluate short-term liquidity relative to the company's equity base.
Takeda Pharmaceutical Co Ltd ADR Competitors by Total Liabilities
The table below lists competitors of Takeda Pharmaceutical Co Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Occidental Petroleum Corporation
NYSE:OXY
|
USA | $40.90 Billion |
|
Sandvik AB
ST:SAND
|
Sweden | Skr81.89 Billion |
|
Public Storage
NYSE:PSA
|
USA | $10.87 Billion |
|
Target Corporation
NYSE:TGT
|
USA | $44.49 Billion |
|
Diamondback Energy Inc
NASDAQ:FANG
|
USA | $28.09 Billion |
|
VOLVO B (FRIA) UNSP.ADR
F:VOL4
|
Germany | €491.70 Billion |
|
SINGAP.TELE. ADR NEW06/10
F:SIT
|
Germany | €20.53 Billion |
|
Samsung Life
KO:032830
|
Korea | ₩285.85 Trillion |
Liability Composition Analysis (2001–2025)
This chart breaks down Takeda Pharmaceutical Co Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TAK market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.25 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Takeda Pharmaceutical Co Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Takeda Pharmaceutical Co Ltd ADR (2001–2025)
The table below shows the annual total liabilities of Takeda Pharmaceutical Co Ltd ADR from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $7.31 Trillion | -6.67% |
| 2024-03-31 | $7.83 Trillion | +3.05% |
| 2023-03-31 | $7.60 Trillion | +1.45% |
| 2022-03-31 | $7.49 Trillion | -3.11% |
| 2021-03-31 | $7.74 Trillion | -4.43% |
| 2020-03-31 | $8.09 Trillion | -7.06% |
| 2019-03-31 | $8.71 Trillion | +316.87% |
| 2018-03-31 | $2.09 Trillion | -13.20% |
| 2017-03-31 | $2.41 Trillion | +32.76% |
| 2016-03-31 | $1.81 Trillion | -13.26% |
| 2015-03-31 | $2.09 Trillion | +3.03% |
| 2014-03-31 | $2.03 Trillion | +17.10% |
| 2013-03-31 | $1.73 Trillion | +15.09% |
| 2012-03-31 | $1.51 Trillion | +131.65% |
| 2011-03-31 | $649.75 Billion | -1.33% |
| 2010-03-31 | $658.53 Billion | -6.77% |
| 2009-03-31 | $706.35 Billion | +34.10% |
| 2008-03-31 | $526.75 Billion | -13.84% |
| 2007-03-31 | $611.38 Billion | -11.89% |
| 2006-03-31 | $693.87 Billion | +27.54% |
| 2005-03-31 | $544.02 Billion | -1.92% |
| 2004-03-31 | $554.65 Billion | +12.82% |
| 2003-03-31 | $491.64 Billion | -2.82% |
| 2002-03-31 | $505.88 Billion | +1.65% |
| 2001-03-31 | $497.69 Billion | -- |
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more